Emerging Advances in Bipolar Therapeutics

Bipolar disorders are a group of brain disorders that cause extreme fluctuation in a person’s mood, energy, and ability to function. The conventional medications used for the treatment of bipolar disorders are Glycogen synthase kinase-3, Brain-derived neurotrophic factor, Phosphoinositide pathway and Protein Kinase C and HDAC inhibitors. These medications help with mood stabilization, neuroprotection, neuroplasticity associated with bipolar disorders. Due to the certain limitations such as inadequate efficacy, substantial side effects, delayed efficacy of this medication’s researchers are exploring new targets and mechanisms. The emerging novel approaches in bipolar therapeutics acts on Glutamatergic pathway, Melatoninergic system, Mitochondrial function, Purinergic system, Insulin signaling pathway, Hypothalamic-pituitary-adrenal axis, Cholinergic neurotransmission, Neuropeptide converting endopeptidase. Additional investigation is essential to validate the enduring protection, acceptance, and effectiveness of new approaches. Timely identification and targeted intervention hold promise to hinder disease progression and mitigate the impact of the condition, emphasizing the importance of continued exploration and development of impactful solutions.